ELVN
NASDAQEnliven Therapeutics Inc.
$44.22+0.39 (+0.88%)
News25/Ratings7
Price$44.22+0.22 (+0.49%)
01:30 PM07:45 PM
News · 26 weeks61-50%
2025-11-022026-04-26
Mix2790d
- Insider19(70%)
- SEC Filings5(19%)
- Other2(7%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECSEC Form PRE 14A filed by Enliven Therapeutics Inc.PRE 14A - Enliven Therapeutics, Inc. (0001672619) (Filer)
- INSIDERSEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Collins Helen Louise4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Enliven Therapeutics Inc.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECSEC Form S-8 filed by Enliven Therapeutics Inc.S-8 - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECSEC Form 10-K filed by Enliven Therapeutics Inc.10-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- SECEnliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
- PREnliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateReported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e
- PREnliven Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceBOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. ET.The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.About Enliven TherapeuticsEnliven is a clinic
- INSIDERDirector Heyman Richard A. sold $32,196 worth of shares (1,230 units at $26.18) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise exercised 45,000 shares at a strike of $2.48 and sold $1,177,862 worth of shares (45,000 units at $26.17) (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Director Kunkel Lori Anne4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Director Heyman Richard A.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Director Gupta Rishi4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Director Garland J. Scott4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Director Derynck Mika K4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Director Bauer Jake4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERSEC Form 4 filed by Director Ballal Rahul D.4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF OPERATING OFFICER Patel Anish was granted 20,000 shares (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P was granted 18,750 shares (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Hohl Benjamin was granted 25,000 shares, increasing direct ownership by 69% to 61,000 units (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Collins Helen Louise was granted 25,000 shares (SEC Form 4)4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
- SECSEC Form 144 filed by Enliven Therapeutics Inc.144 - Enliven Therapeutics, Inc. (0001672619) (Subject)